All Articles
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
Late-Breaking HOPA News: Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease on Denosumab Therapy
Originally approved for the treatment of osteoporosis in postmenopausal women at high risk for fractures, denosumab is now frequently used in the management of hypercalcemia of malignancy and to decrease skeletal-related events for certain cancer patients
Late-Breaking HOPA News: T-cell Malignancies with CAR T-cell therapy
In November 2023, the FDA announced their investigation of reports of T-cell lymphomas from clinical trials and post-marketing adverse event data sources for CAR T-cell immunotherapies. In January 2024, the FDA issued Safety Labeling Change notification.
Pharmacist’s Application to Practice: Nirogacestat (Ogsiveo)
Brooke Lochridge, PharmD ,PGY-2 Oncology Pharmacy Resident, of Tristar Centennial Medical Center, Nashville, TN, and Colleen McCabe, PharmD, BCOP, Oncology Clinical Specialist, Sarcoma & Melanoma from Vanderbilt University Medical Center, Nashville, TN w